N/A N=402 Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Cystic Fibrosis
Primary: Orocaecal Transit Time — 330; 210 minutes — p=0.04
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
N/A N=47 Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Weight Percentile at 3 Months — 33.5; 31.0 Weight Percentile, sex and age adjusted
Phase 4 N=40 Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis
Cystic Fibrosis · Dysbiosis
Primary: Shannon Index — 5.02; 4.96; 5.28; 5.73 Shannon index
Phase 3 N=41 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake
Phase 2 N=64 Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
N/A N=79 Cystic Fibrosis Related Bone Disease: the Role of CFTR
Cystic Fibrosis Related Bone Disease
Primary: Bone Microarchitecture and Strength Measures of the Radius and Tibia — 44.6; 40.1; 43.7 mgHA/cm3 — p=0.77
N/A N=26 Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months…
Phase 3 N=32 Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Cystic Fibrosis
Primary: Coefficient of Fat Absorption (%) — 88.62; 49.78 Percentage — p=<0.001
Phase 2 N=19 Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
Pancreatic Insufficiency · Cystic Fibrosis
Primary: Coefficient of Fat Absorption — 80; 77 % fat absorption
Phase 3 N=19 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants
N/A N=10 Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Cystic Fibrosis · Lung Transplant
Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…
Phase 3 N=17 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Coefficient of Fat Absorption (%) — 47.41; 82.81 Percentage — p=<0.001
Phase 2 N=13 Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety of Adrulipase — 2 Participants
N/A N=24 Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Cystic Fibrosis · Exocrine Pancreatic Insufficiency · Pancreatic Diseases
Primary: Number of Patients With Adverse Drug Reaction — 1 participants
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Phase 3 N=40 A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
Exocrine Pancreatic Insufficiency · Steatorrhea · Malabsorption Syndromes
Primary: Change in the Coefficient of Fat Absorption (COA-fat Percent) — -34.1; -1.5 percentage COA-fat — p=<0.001
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=10 Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Sweat Chloride Concentration — NA mmol/L
N/A N=50 Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Phase 2 N=60 The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Weight-for-age Z-score — -0.018; 0.045 Z-score — p=0.2521
N/A N=9 Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis
Constipation · Cystic Fibrosis
Primary: Number of Spontaneous Bowel Movements Per Week — 9.7; 10.8; 8.8 bowel movements
Phase 2 N=17 Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks
Phase 3 N=238 Study of Ataluren (PTC124™) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 3 N=49 Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Percentage of Patients With Control of Steatorrhea — 46.9; 42.9 percentage of patients
N/A N=267 Early Intervention in Cystic Fibrosis Exacerbation
Cystic Fibrosis
Primary: Change in FEV1 — -0.07; -0.08 Liters
Phase 3 N=33 Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percent Coefficient of Fat Absorption (CFA%) — 88.28; 62.76 percent CFA — p=<0.001